SCHEMBL6134086

SCHEMBL6134086

COc1ccc(CC(=O)c2ccccc2Br)nn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.41
KDM4E B2RXH2 3/20 0.41
NNMT P40261 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
HPGD P15428 2/20 0.40
USP2 O75604 1/20 0.40
TP53 P04637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
KMT2A Q03164 2/20 0.39
RAB9A P51151 3/20 0.37
NPC1 O15118 1/20 0.37
GAA P10253 1/20 0.37
GUSB P08236 1/20 0.37
TSHR P16473 1/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6133505 0.84 NPC1 (0.50) ALDH1A1KDM4ENNMTSMN1; SMN2L3MBTL1
SCHEMBL6133746 0.84 NPC1 (0.44) ALDH1A1KDM4ENNMTSMN1; SMN2USP2
SCHEMBL6134151 0.79 NNMT (0.45) ALDH1A1KDM4ENNMTSMN1; SMN2HPGD
SCHEMBL6133870 0.77 GSK3B (0.43) ALDH1A1KDM4ENNMTSMN1; SMN2HPGD
SCHEMBL6134112 0.75 NPC1 (0.45) ALDH1A1KDM4ENNMTHPGDL3MBTL1
SCHEMBL6134262 0.74 NNMT (0.42) ALDH1A1NNMTSMN1; SMN2KMT2ARAB9A
SCHEMBL6134928 0.74 NNMT (0.42) NNMTSMN1; SMN2KMT2ARAB9ANPC1
SCHEMBL6134635 0.74 SMN1; SMN2 (0.44) ALDH1A1KDM4ENNMTSMN1; SMN2HSD17B10
SCHEMBL5799347 0.72 NPC1 (0.48) ALDH1A1NNMTSMN1; SMN2L3MBTL1KMT2A
SCHEMBL6295186 0.72 USP2 (0.70) ALDH1A1KDM4ESMN1; SMN2HPGDUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ASTELLAS PHARMA INC. (JP) 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ADORA2B, ADORA2A, ADORA1 ALDH1A1 801/4885KDM4E 3364/4885NNMT 2041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.